- Home
- LZB vs BCYC Comparison
LZB vs BCYC Comparison
Compare LZB & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LZB
- BCYC
- Stock Information
- Founded
- LZB 1927
- BCYC 2009
- Country
- LZB United States
- BCYC United Kingdom
- Employees
- LZB N/A
- BCYC N/A
- Industry
- LZB Home Furnishings
- BCYC Biotechnology: Pharmaceutical Preparations
- Sector
- LZB Consumer Discretionary
- BCYC Health Care
- Exchange
- LZB Nasdaq
- BCYC Nasdaq
- Market Cap
- LZB 1.8B
- BCYC 1.7B
- IPO Year
- LZB N/A
- BCYC 2019
- Fundamental
- Price
- LZB $44.86
- BCYC $13.34
- Analyst Decision
- LZB Hold
- BCYC Buy
- Analyst Count
- LZB 1
- BCYC 9
- Target Price
- LZB N/A
- BCYC $34.50
- AVG Volume (30 Days)
- LZB 372.6K
- BCYC 412.4K
- Earning Date
- LZB 02-18-2025
- BCYC 02-18-2025
- Dividend Yield
- LZB 1.94%
- BCYC N/A
- EPS Growth
- LZB 4.44
- BCYC N/A
- EPS
- LZB 2.90
- BCYC N/A
- Revenue
- LZB $2,070,500,000.00
- BCYC $36,898,000.00
- Revenue This Year
- LZB $3.32
- BCYC $40.69
- Revenue Next Year
- LZB $3.97
- BCYC N/A
- P/E Ratio
- LZB $15.59
- BCYC N/A
- Revenue Growth
- LZB N/A
- BCYC 48.60
- 52 Week Low
- LZB $32.00
- BCYC $12.17
- 52 Week High
- LZB $46.47
- BCYC $28.67
- Technical
- Relative Strength Index (RSI)
- LZB 58.47
- BCYC 34.88
- Support Level
- LZB $44.33
- BCYC $13.20
- Resistance Level
- LZB $44.52
- BCYC $15.43
- Average True Range (ATR)
- LZB 1.06
- BCYC 0.89
- MACD
- LZB 0.14
- BCYC 0.16
- Stochastic Oscillator
- LZB 81.40
- BCYC 6.17
About LZB La-Z-Boy Incorporated
La-Z-Boy Inc is a U.S.-based company that manufactures, distributes, and retails upholstery furniture products. It is a producer of reclining chairs and distributors of residential furniture in the U.S. The company chiefly operates in the United States but also has secondary operations in Canada and other countries. The company's reportable segments include the Wholesale segment, which manufactures and imports upholstered furniture; and Retail, which sells upholstered and case goods furniture to the end consumer. The majority of the company's revenue is derived from its Wholesale segment.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.